Abstract

Research Article

The value of bone scans to predict survival time in patients with diagnosed prostate cancer: single-center retrospective study

Elif Marangoz, Doğangün Yüksel*, Olga Yaylalı, Saadettin Yılmaz Eskiçorapçı, Nilay Şen, Hülya Aybek and Fatma Suna Kıraç

Published: 25 May, 2022 | Volume 6 - Issue 2 | Pages: 004-011

Objective: In this study, we investigated the significance of the bone scan results as a prognostic factor to predict survival by comparing age, serum PSA level, and Gleason score. 
Methods: Medical records of 313 patients were retrospectively examined. 265 patients of 313 were included in the study. 
Results: 202 (76%) patients of 265 were still alive and 63 (24%) patients of 265 were dead because of prostate cancer. Patients’ mean estimated survival times for those with, without, and suspected bone metastases were 47.4 ± 5.4 months, 159.1 ± 8.6 months, and 71.1 ± 14.4 months, respectively (p = 0.0001). While the mean estimated survival time of < 70 years patients old was 137.1 ± 9.4 months, the mean estimated survival time of ≥ 70 years old patients was 78.2 ± 5.0 
(p = 0.031). 243 patients with known PSA values, of those whose PSA levels were < 10 ng/ml, between 10-20 ng/ml, between > 20-50 ng/ml, and > 50 ng/ml, the estimated mean survival time was 
106.9 ± 4.2 months, 118.1 ± 14.8 months, 87.6 ± 7.4 months and 51.7 ± 6.2 month, respectively and a significant difference was determined (p = 0.0001). For patients whose Gleason scores were < 7, 7,
and >7, the mean estimated survival time was 167.5 ± 10.8 months), 86.8 ± 5.5 months, and 
61.0 ± 5.4 months, respectively, and a significant difference was determined (p = 0.0001). 
Conclusion: We identified that the estimated mean survival time of the patients who had bone metastases, had a high level of PSA, had a high level of Gleason score, and were older than 70 years old was shorter than other groups. We concluded the most important prognostic factor affecting survival time independently was the finding of metastasis detected in bone scintigraphy.

Read Full Article HTML DOI: 10.29328/journal.jro.1001040 Cite this Article Read Full Article PDF

Keywords:

Prostate cancer; Bone scintigraphy; Survival; Bone metastases

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8. PMID: 30620402.
  2. Güney Y, Yılmaz S, Türkcü Ü, Kurtman C. Kemik metastazlarında tanı ve tedavi. Acta Oncologica Turcica. 2008;41:1-6.
  3. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25. PMID: 27568654.
  4. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P; American Urological Association. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013 Jan;189(1 Suppl):S2-S11. doi: 10.1016/j.juro.2012.11.014. PMID: 23234625.
  5. Hirobe M, Takahashi A, Hisasue S, Kitamura H, Kunishima Y, Masumori N, Iwasawa A, Fujimori K, Hasegawa T, Tsukamoto T. Bone scanning--who needs it among patients with newly diagnosed prostate cancer? Jpn J Clin Oncol. 2007 Oct;37(10):788-92. doi: 10.1093/jjco/hym097. Epub 2007 Oct 2. PMID: 17911377.
  6. Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, Ichihara K, Yonese J, Koizumi M, Nakashima J, Fujii H. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer. 2002 Feb 15;94(4):964-72. PMID: 11920464.
  7. Ayyathurai R, Mahapatra R, Rajasundaram R, Srinivasan V, Archard NP, Toussi H. A study on staging bone scans in newly diagnosed prostate cancer. Urol Int. 2006;76(3):209-12. doi: 10.1159/000091620. PMID: 16601380.
  8. Pal RP, Thiruudaian T, Khan MA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl. 2008 Nov;10(6):890-5. doi: 10.1111/j.1745-7262.2008.00427.x. PMID: 18958353.
  9. Spencer JA, Chng WJ, Hudson E, Boon AP, Whelan P. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. Br J Radiol. 1998 Nov;71(851):1130-5. doi: 10.1259/bjr.71.851.10434906. PMID: 10434906.
  10. O'Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int. 2003 Nov;92(7):685-9. doi: 10.1046/j.1464-410x.2003.04480.x. PMID: 14616446.
  11. Tekdoğan ÜY, Ortapamuk H, Oğuz H, Başar MM, Naldöken S, Atan A. Prostat kanserli hastalarda prostat spesifik antijen (PSA) kemik metastazlarının belirleyicisi midir? Türk Üroloji Dergisi. 2001;27:433-436.
  12. Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT,  Pearson Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445-1451.
  13. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988 Jan 1;61(1):195-202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. PMID: 3334948.
  14. Ishikawa S, Soloway MS, Van der Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol. 1989 May;141(5):1139-42. doi: 10.1016/s0022-5347(17)41193-1. PMID: 2651713.
  15. Lund F, Smith PH, Suciu S. Do bone scans predict prognosis in prostatic cancer? A report of the EORTC protocol 30762. Br J Urol. 1984 Feb;56(1):58-63. doi: 10.1111/j.1464-410x.1984.tb07165.x. PMID: 6697108.
  16. Lund F, Smith PH, Suciu S. Do bone scans predict prognosis in prostatic cancer? A report of the EORTC protocol 30762. Br J Urol. 1984 Feb;56(1):58-63. doi: 10.1111/j.1464-410x.1984.tb07165.x. PMID: 6697108.
  17. Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer. 2008 Nov 15;113(10):2695-703. doi: 10.1002/cncr.23885. PMID: 18853417.
  18. Pollen JJ, Gerber K, Ashburn WL, Schmidt JD. Nuclear bone imaging in metastatic cancer of the prostate. Cancer. 1981 Jun 1;47(11):2585-94. doi: 10.1002/1097-0142(19810601)47:11<2585::aid-cncr2820471113>3.0.co;2-u. PMID: 6266636.
  19. Hamdy FC. Prognostic and predictive factors in prostate cancer. Cancer Treat Rev. 2001 Jun;27(3):143-51. doi: 10.1053/ctrv.2000.0208. PMID: 11417964.
  20. Yamashita K, Denno K, Ueda T, Komatsubara Y, Kotake T, Usami M, Maeda O, Nakano S, Hasegawa Y. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer. 1993 Feb 15;71(4):1297-302. doi: 10.1002/1097-0142(19930215)71:4<1297::aid-cncr2820710421>3.0.co;2-s. PMID: 8435807.
  21. Tanaka N, Fujimoto K, Shinkai T, Nakai Y, Kuwada M, Anai S, Miyake M, Hirayama A, Hasegawa M, Hirao Y. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis. Jpn J Clin Oncol. 2011 Oct;41(10):1209-13. doi: 10.1093/jjco/hyr118. Epub 2011 Aug 23. PMID: 21862505.
  22. Zaman MU, Fatima N, Sajjad Z. Metastasis on bone scan with low prostate specific antigen (≤20 ng/ml) and Gleason's score (<8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines? Asian Pac J Cancer Prev. 2011;12(6):1529-32. PMID: 22126493.
  23. Lai MH, Luk WH, Chan JC. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population. Urol Oncol. 2011 May-Jun;29(3):275-9. doi: 10.1016/j.urolonc.2009.05.007. Epub 2009 Sep 6. PMID: 19734069.
  24. Ishizuka O, Tanabe T, Nakayama T, Kawakami M, Kinebuchi Y, Nishizawa O. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan. Int J Urol. 2005 Aug;12(8):728-32. doi: 10.1111/j.1442-2042.2005.01118.x. PMID: 16174046.
  25. Al-Ghazo MA, Ghalayini IF, Al-Azab RS, Bani-Hani I, Barham A, Haddad Y. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study. Int Braz J Urol. 2010 Nov-Dec;36(6):685-91; discussion 691-2. doi: 10.1590/s1677-55382010000600006. PMID: 21176275.
  26. Lee SH, Chung MS, Park KK, Yom CD, Lee DH, Chung BH. Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL? World J Urol. 2012 Apr;30(2):265-9. doi: 10.1007/s00345-011-0728-6. Epub 2011 Jul 16. PMID: 21779835; PMCID: PMC3321272.
  27. Salonia A, Gallina A, Camerota TC, Picchio M, Freschi M, DaPozzo LF, Guazzoni G, Fazio F, Rigatti P, Montorsi F. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology. 2006 Aug;68(2):362-6. doi: 10.1016/j.urology.2006.02.009. PMID: 16904453.
  28. Ritenour CW, Abbott JT, Goodman M, Alazraki N, Marshall FF, Issa MM. The utilization of Gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients. ScientificWorldJournal. 2009 Oct 2;9:1040-5. doi: 10.1100/tsw.2009.113. PMID: 19802499; PMCID: PMC5823094.
  29. Rigaud J, Tiguert R, Le Normand L, Karam G, Glemain P, Buzelin JM, Bouchot O. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol. 2002 Oct;168(4 Pt 1):1423-6. doi: 10.1097/01.ju.0000030900.55714.76. PMID: 12352409.
  30. Knudson G, Grinis G, Lopez-Majano V, Sansi P, Targonski P, Rubenstein M, Sharifi R, Guinan P. Bone scan as a stratification variable in advanced prostate cancer. Cancer. 1991 Jul 15;68(2):316-20. doi: 10.1002/1097-0142(19910715)68:2<316::aid-cncr2820680218>3.0.co;2-0. PMID: 2070330.
  31. Ohmori K, Matsui H, Yasuda T, Kanamori M, Yudoh K, Seto H, Tsuji H. Evaluation of the prognosis of cancer patients with metastatic bone tumors based on serial bone scintigrams. Jpn J Clin Oncol. 1997 Aug;27(4):263-7. doi: 10.1093/jjco/27.4.263. PMID: 9379516.
  32. Wyatt RB, Sánchez-Ortiz RF, Wood CG, Ramirez E, Logothetis C, Pettaway CA. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc. 2004 Dec;96(12):1587-93. PMID: 15622688; PMCID: PMC2568655.
  33. Obek C, Lai S, Sadek S, Civantos F, Soloway MS. Age as a prognostic factor for disease recurrence after radical prostatectomy. Urology. 1999 Sep;54(3):533-8. doi: 10.1016/s0090-4295(99)00168-5. PMID: 10475367.
  34. He J, Zeng ZC, Yang P, Chen B, Jiang W, Du SS. Clinical features and prognostic factors for patients with bone metastases from prostate cancer. Asian J Androl. 2012 May;14(3):505-8. doi: 10.1038/aja.2012.24. Epub 2012 Apr 16. PMID: 22504872; PMCID: PMC3720166.
  35. Abu-Hamar Ael H, Gameel TA. Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer Under Palliative Androgen Deprivation Treatment. J Egypt Natl Canc Inst. 2009 Sep;21(3):229-36. PMID: 21132033.

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?